publication venue for
-
A multi‐institutional feasibility lead‐in trial of lymphatic mapping with
SPECT –CT for evaluating contralateral disease in lateralized oropharynx cancer using 99m‐technetium sulfur colloid. 46:3038-3045. 2024 -
Circulating tumor
HPV DNA in the management ofHPV + oropharyngeal cancer and its correlation withMRI . 46:2206-2213. 2024 -
It is time to improve the diagnostic workup of oropharyngeal cancer with circulating tumor
HPV DNA : Systematic review and meta‐analysis. 45:2945-2954. 2023 -
Comparing prognostic utility between the 8th edition of
TNM staging system and the lymph node ratio for oral squamous cell carcinoma. 43:2876-2882. 2021 -
Considerations for head and neck oncology practices during the coronavirus disease 2019 (
COVID ‐19) pandemic: Wuhan and Toronto experience. 42:1202-1208. 2020 - Prospective evaluation of pretreatment and intratreatment FDG PET‐CT SUV stability in primary head and neck cancer. 41:1889-1894. 2019
- Salvage laryngectomy and laryngopharyngectomy: Multicenter review of outcomes associated with a reconstructive approach. 41:16-29. 2019
- Pretreatment neurocognitive function and self‐reported symptoms in patients with newly diagnosed head and neck cancer compared with noncancer cohort. 40:2029-2042. 2018
- MicroRNA expression as predictor of local recurrence risk in oral squamous cell carcinoma. 38:E189-E197. 2016
- Role of primary surgery in the treatment of advanced oropharyngeal cancer. 38:E571-E579. 2016
- Impact of the addition of chemotherapy to radiotherapy for oropharyngeal cancer in 2003–2004: Population‐based study from the Province of Ontario, Canada. 37:1461-1469. 2015
- Quality of life instruments for skull base pathology: Systematic review and methodologic appraisal. 35:1221-1231. 2013
- Physical morbidity by surgical approach and tumor location in skull base surgery. 35:493-499. 2013
- Predictive value of metastatic cervical lymph node ratio in papillary thyroid carcinoma recurrence. 35:592-598. 2013
- Effect of an interdisciplinary rehabilitation program on quality of life in patients with head and neck cancer: Review of clinical experience. 35:343-349. 2013
- Patient preferences for oropharyngeal cancer treatment de‐escalation. 35:151-159. 2013
- Acute‐phase response reactants as objective biomarkers of radiation‐induced mucositis in head and neck cancer. 34:985-993. 2012
- Percutaneous treatment of facial venous malformations: a matched comparison of alcohol and bleomycin sclerotherapy.. 33:125-130. 2011
- Fluorescence in situ hybridization gene amplification analysis of EGFR and HER2 in patients with malignant salivary gland tumors treated with lapatinib. 31:1006-1012. 2009
- Patient perception of risk factors in head and neck cancer. 31:355-360. 2009
- Esthesioneuroblastoma: The Princess Margaret Hospital experience. 30:1607-1614. 2008
- Prognostic value of postsurgical stimulated thyroglobulin levels after initial radioactive iodine therapy in well‐differentiated thyroid carcinoma. 30:693-700. 2008
- Mutant p53 proteins: Between loss and gain of function. 29:488-496. 2007
- Association between smoking during radiotherapy and prognosis in head and neck cancer: A follow‐up study. 24:1031-1037. 2002
- Digital necrosis associated with squamous cell carcinoma of the tonsil. 24:1019-1021. 2002
- Comparison of the addition of T and N integer scores with TNM stage groups in head and neck cancer. 15:497-503. 1993
- Sternocleidomastoid flap following parotidectomy. 12:430-435. 1990
- Survival results from a phase III study of simultaneous versus 1‐hour sequential methotrexate—5‐fluorouracil chemotherapy in head and neck cancer. 8:146-152. 1986